BFNH · Bioforce Nanosciences Holdings, Inc. · Executive Compensation
$7.55
-1.17 (-13.42%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has reported recurring losses from operations and has net current liabilities and an accumulated deficit. These conditions raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$286.17M
Shares
33.55M
Volume · Oct 2
8358
Avg daily vol (3M)
9603
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard Kaiser | interim Chief Executive Officer | Appointed | 2026-06-18 |
| Scott Mager | Director | Appointed | 2026-06-18 |
| Sasha Shapiro | Vice-President | Resigned | 2026-06-18 |
| John LaViolette | Co-Chief Executive Officer (Co-CEO) | Resigned | 2026-06-18 |
| Steven Gagnon | Co-Chief Executive Officer (Co-CEO) | Resigned | 2026-06-18 |